Factors that influence the bleeding phenotype in severe hemophilic patients

被引:18
作者
Rendo, Pablo [1 ]
Shafer, Frank [1 ]
Korth-Bradley, Joan M. [1 ]
Sivamurthy, Krupa [1 ]
Korin, Jorge [2 ]
机构
[1] Pfizer Inc, Collegeville, PA 19426 USA
[2] Consultorios Hematol, Buenos Aires, DF, Argentina
关键词
blood coagulation disorder; hemophilia A; hemophilia B; inherited; ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; RHEUMATOID-ARTHRITIS; CLINICAL SEVERITY; FACTOR-VIII; PROPHYLACTIC TREATMENT; PROMOTER POLYMORPHISM; VENOUS THROMBOSIS; DISEASE-ACTIVITY;
D O I
10.1097/MBC.0b013e3283614210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemophilia A and B are rare, X-linked bleeding disorders resulting from a partial or total deficiency of functionally active coagulation factor VIII or factor IX, respectively. Endogenous factor levels have traditionally been used to characterize the severity of the disorder, with severe hemophilia considered as circulating levels of factor less than 1% of normal. Identifying patients with severe hemophilia is essential to effective treatment, since these patients are at highest risk of spontaneous life or limb-threatening bleeding and disability resulting from repeated joint bleeding and are most likely to benefit from prophylaxis. However, there is variability in bleeding tendency, even among patients with severe hemophilia. This article will review potential modifiers of hemophilia-associated bleeding other than endogenous factor activity, which may influence bleeding tendencies and complications in hemophilic patients considered to have severe hemophilia. These potential modifiers include physiologic factors, such as elements of the hemostatic system; pathophysiologic factors, such as hemophilic arthropathy, associated inflammation, and angiogenesis; and others, such as seasonal variation, body weight, and physical activity. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:683 / 690
页数:8
相关论文
共 72 条
[11]   Hereditary Hemochromatosis Is Characterized by a Clinically Definable Arthropathy That Correlates With Iron Load [J].
Carroll, G. J. ;
Breidahl, W. H. ;
Bulsara, M. K. ;
Olynyk, J. K. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (01) :286-294
[12]   HFE mutations in the pathobiology of hemophilic arthropathy [J].
Cruz, E ;
Porto, G ;
Morais, S ;
Campos, M ;
de Sousa, M .
BLOOD, 2005, 105 (08) :3381-3382
[13]   Clinical severity of haemophilia A: does the classification of the 1950s still stand? [J].
Den Uijl, I. E. M. ;
Bunschoten, E. P. Mauser ;
Roosendaal, G. ;
Schutgens, R. E. G. ;
Biesma, D. H. ;
Grobbee, D. E. ;
Fischer, K. .
HAEMOPHILIA, 2011, 17 (06) :849-853
[14]   Association between haemophilia and inherited thrombophilia: a single centre survey [J].
Di Perna, C. ;
Franchini, M. ;
Riccardi, F. ;
Rivolta, G. F. ;
Angeri, F. ;
Tagliaferri, A. .
HAEMOPHILIA, 2011, 17 (01) :161-162
[15]   High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies [J].
Drouart, M ;
Saas, P ;
Billot, M ;
Cedoz, JP ;
Tiberghien, P ;
Wendling, D ;
Toussirot, É .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (01) :158-162
[16]  
Dykes AC, 2001, BRIT J HAEMATOL, V113, P636
[17]  
Ettingshausen CE, 2001, THROMB HAEMOSTASIS, V85, P218
[18]   Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay [J].
Ghosh, K ;
Shetty, S ;
Mohanty, D .
HAEMOPHILIA, 2001, 7 (01) :9-12
[19]   ACTIVATED PROTEIN-C RESISTANCE CAUSED BY ARG506GLN MUTATION IN FACTOR VA [J].
GREENGARD, JS ;
SUN, X ;
XU, X ;
FERNANDEZ, JA ;
GRIFFIN, JH ;
EVATT, B .
LANCET, 1994, 343 (8909) :1361-1362
[20]  
GRIFFIN JH, 1993, BLOOD, V82, P1989